PROTOCOL

Rotenone as Potential Repurposed Drug to Suppress Metastasis 
Protocol ITN019AD
Phase II, Double-Blinded, Placebo-Controlled, Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with Omalizumab, an Anti-IgE Monoclonal Antibody
Allergen Immunotherapy Co-Administered with Omalizumab
BB-IND # 9996
Version 8.0 (September 10, 2017)
Confidentiality Statement
The information contained within this document is not to be disclosed in any way without the prior permission of the Principal Investigator, the Cancer Network, or the National Institute of Cancer
Principal Investigator: John Smith, MD
Director of Clinical Research, Creighton University School of Medicine Chief of Cancer Therapies, Professor of Medicine
Creighton University
601 North 30th Street, Suite #5850
Omaha, NE 68131
Phone: (402) 180-2940
Fax: (402) 283-4113
E-mail: johnsmith@creighton.edu
Version 8.0 â€“ September 10, 2004

...
...
...
...
...
...
...
...
...